We are live on ! Find out more
LP

LMR Partners Portfolio holdings

AUM $45.4B
1-Year Est. Return 60.68%
This Fund
S&P 500
This Quarter Est. Return
+14.07%
1 Year Est. Return
+60.68%
3 Year Est. Return
+183.94%
5 Year Est. Return
+215.13%
10 Year Est. Return
+663.15%
AUM
$6.45B
AUM Growth
+$725M
Cap. Flow
-$581M
Cap. Flow %
-9%
Top 10 Hldgs %
18%
Holding
1,317
New
227
Increased
165
Reduced
129
Closed
313

Sector Composition

Rank Sector Weight
1 Financials 13.98%
2 Technology 9.11%
3 Energy 6.09%
4 Healthcare 4.57%
5 Utilities 4.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
UNM icon
751
Unum
UNM
$14B
$280K ﹤0.01%
7,082
-18,563
-72% -$767K
AIG icon
752
American International
AIG
$42.9B
$277K ﹤0.01%
+5,496
New +$321K
INBX
753
DELISTED
Inhibrx, Inc. Common Stock
INBX
$273K ﹤0.01%
14,458
VORBW
754
DELISTED
Virgin Orbit Holdings, Inc. Warrant
VORBW
$271K ﹤0.01%
1,352,908
HAYW icon
755
Hayward Holdings
HAYW
$3.28B
$267K ﹤0.01%
+22,786
New +$279K
XBPEW
756
XBP Europe Holdings Warrant
XBPEW
$266K ﹤0.01%
25,000
IWO icon
757
iShares Russell 2000 Growth ETF
IWO
$14.4B
$265K ﹤0.01%
+1,169
New +$267K
MKFG.WS
758
DELISTED
Markforged Holding Corporation Warrants, each whole warrant exercisable to purchase one-tenth (1/10th) of a share of Common Stock at an exercise price of $115.00 per share
MKFG.WS
$264K ﹤0.01%
275,450
SCLX icon
759
Scilex Holding
SCLX
$48M
$262K ﹤0.01%
+913
New +$253K
PH icon
760
Parker-Hannifin
PH
$125B
$261K ﹤0.01%
+776
New +$257K
LVAC
761
DELISTED
LAVA Medtech Acquisition Corp. Class A Common Stock
LVAC
$261K ﹤0.01%
25,000
APEN
762
DELISTED
Apollo Endosurgery, Inc.
APEN
$260K ﹤0.01%
+26,184
New +$259K
GCTS.WS
763
GCT Semiconductor Holding Warrants
GCTS.WS
$14.5M
$259K ﹤0.01%
25,000
OPAD.WS
764
DELISTED
Offerpad Solutions Inc. Warrants, Every 15 warrants will be exercisable for one share of Class A Common Stock at an exercise price of $172.50 per share of Class A Common Stock
OPAD.WS
$258K ﹤0.01%
490,220
CECO icon
765
Ceco Environmental
CECO
$3.94B
$257K ﹤0.01%
18,368
+2,132
+13% +$30.1K
NVEC icon
766
NVE Corp
NVEC
$564M
$256K ﹤0.01%
+3,088
New +$231K
HROW icon
767
Harrow
HROW
$1.47B
$256K ﹤0.01%
12,093
+1,117
+10% +$19K
RMGCW
768
DELISTED
RMG Acquisition Corp. III Warrant
RMGCW
$255K ﹤0.01%
25,000
ARQT icon
769
Arcutis Biotherapeutics
ARQT
$3.55B
$255K ﹤0.01%
23,145
ALDX icon
770
Aldeyra Therapeutics
ALDX
$95.3M
$254K ﹤0.01%
25,585
-619
-2% -$4.38K
MVLAW
771
DELISTED
Movella Holdings Inc. Warrant
MVLAW
$252K ﹤0.01%
185,632
+109,301
+143% +$19.1K
IOVA icon
772
Iovance Biotherapeutics
IOVA
$2.1B
$252K ﹤0.01%
41,211
-10,000
-20% -$69K
HOG icon
773
Harley-Davidson
HOG
$2.66B
$252K ﹤0.01%
6,631
-19,106
-74% -$840K
RPC
774
Ridgepost Capital
RPC
$971M
$251K ﹤0.01%
24,813
+5,301
+27% +$57K
SRRK icon
775
Scholar Rock
SRRK
$5.92B
$249K ﹤0.01%
31,101
+12,302
+65% +$125K

Similar funds

LMR Partners's Q1 2023 Portfolio in Review

As of Q1 2023, LMR Partners held 1,317 positions worth $6.45B, up 13% from $5.73B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

LMR Partners withdrew a net $581M in Q1 2023, closing 313 positions and reducing 129 holdings. Its most notable exit was Bank of New York Mellon, an estimated $60M position sold in full.

By sector, the portfolio is most concentrated in Financials at 14% of assets, down from 15% a quarter earlier, followed by Technology and Energy.

Against the trend, LMR Partners opened a new position in AstraZeneca worth $42.7M.

  • LMR Partners's largest Q1 2023 buy was AstraZeneca: 307,414 shares worth $42.7M.
  • LMR Partners added most to First Horizon in Q1 2023, an estimated $77.4M increase.
  • LMR Partners's biggest Q1 2023 reduction was TSMC, cutting an estimated $121M.
  • LMR Partners fully exited Bank of New York Mellon in Q1 2023, selling an estimated $60M.
  • LMR Partners's ten largest holdings make up 18% of its $6.45B portfolio in Q1 2023.
  • LMR Partners opened 227 new positions and closed 313 in Q1 2023.
  • LMR Partners's portfolio value rose 13% quarter-over-quarter to $6.45B.

Based on LMR Partners's 13F filing for Q1 2023, filed 15 May 2023.